Table 1.
FPNS N=12 (%)a |
Placebo N=12 (%)a |
All patients N=24 (%)a |
|
---|---|---|---|
Average age (range) | 51.5 (44.7, 58.3) | 53.3 (45.0, 61.6) | 52.4 (47.5, 57.4) |
Female sex | 9 (75.0) | 4 (33.3) | 13 (54.2) |
Race | |||
Caucasian | 8 (66.7) | 8 (66.7) | 16 (66.7) |
Black | 3 (25) | 2 (16.7) | 5 (20.8) |
Hispanic | 1 (8.3) | 2 (16.7) | 3 (12.5) |
Education | |||
High school or less | 4 (33.3) | 2 (16.7) | 6 (25.0) |
College | 8 (66.7) | 7 (58.3) | 15 (62.5) |
Advanced degree | 0 | 3 (25.0) | 3 (12.5) |
Cancer type | |||
Breast | 3 (25.0) | 2 (16.7) | 5 (20.8) |
Gastrointestinal | 2 (16.7) | 4 (33.3) | 6 (25.0) |
Genitourinary | 2 (16.7) | 0 | 2 (8.3) |
Gynecologic | 2 (16.7) | 0 | 2 (8.3) |
Lung | 1 (8.3) | 2 (16.7) | 3 (12.5) |
Hematologic | 0 | 2 (16.7) | 2 (8.3) |
Others | 2 (16.7) | 2 (16.7) | 4 (16.7) |
Cancer stage | |||
Metastatic/refractory | 8 (66.7) | 10 (83.4) | 18 (75.0) |
Localized/Locally advanced | 4 (33.3) | 2 (16.6) | 6 (25.0) |
*Cancer Dyspnea Scale, mean (SD) | |||
Effort | 6.3 (3.7) | 4.6 (2.7) | 5.5 (3.3) |
Anxiety | 3.6 (3.0) | 2.3 (3.7) | 3.0 (3.4) |
Discomfort | 2.8 (1.5) | 2.4 (1.4) | 2.6 (1.4) |
Total | 12.8 (7.1) | 9.3 (5.8) | 11.1 (6.6) |
Average dyspnea NRS during breakthrough episodes over the last week, mean (SD) |
4.4 (1.4) | 4 (1.0) | 4.2 (1.2) |
Co-morbidities | |||
COPD | 2 (16.7) | 2 (16.7) | 4 (16.7) |
Heart failure | 1 (8.3) | 0 | 1 (4.2) |
Asthma | 5 (41.7) | 0 | 5 (20.8) |
Bronchiectasis | 0 | 0 | 0 |
Concurrent therapies | |||
Opioids | 12 (100.0) | 12 (100.0) | 24 (100.0) |
Bronchodilators | 6 (50.0) | 5 (41.7) | 11 (45.8) |
Steroids | 0 | 0 | 0 |
Supplemental oxygen | 1 (8.3) | 1 (8.3) | 2 (8.3) |
Morphine equivalent daily doses, median (interquartile range) in mg |
137.5 (125, 200) | 175 (135, 325) | 158 (133, 235) |
Karnofsky performance status, mean (SD) |
75.8 (9.0) | 75.8 (10.8) | 75.8 (9.7) |
Abbreviations: COPD, chronic obstructive pulmonary disease; NRS, numeric rating scale; SD, standard deviation
unless otherwise specified